Pfizer links up with heart disease AI developer Anumana to build cardiac amyloidosis diagnostics
Related Articles
Global Electrophysiology Devices Market to Surpass US$ 20,069.2 Million by 2030, Says Coherent Market Insights (CMI)
Coherent Market Insights: The global electrophysiology devices market is expected to exhibit a CAGR of 12.6% during the forecast period due to the increasing organic strategies such as acquisition by…February 14, 2023
Anumana’s ECG-AI™ Algorithms Honored with 2024 MedTech Breakthrough Award for “Best New Technology Solution-Cardiology”
Anumana’s innovative AI algorithms recognized for their transformative potential in cardiology - the first of which is now commercially availableMay 09, 2024
Midwest providers eye new financial opportunities
Modern Healthcare: Mayo Clinic announced a new technology platform initiative to deliver the next generation of clinical decision support tools, diagnostic insights and care recommendations to help clinicians make faster…April 18, 2021
Anumana wins FDA clearance for ECG-AI algorithm
Mass Device: Anumana announced that it received FDA 510(k) clearance for its AI-powered ECG-AI LEF medical device.October 03, 2023